Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
11 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
Current reports
8-K
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8 Jan 24
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 Dec 23
8-K
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
7 Nov 23
8-K
Regulation FD Disclosure
18 Oct 23
8-K
Termination of a Material Definitive Agreement
26 Sep 23
8-K
Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
8 Aug 23
8-K
Caribou Biosciences Announces Proposed Public Offering of Common Stock
14 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
11 Mar 24
424B5
Prospectus supplement for primary offering
14 Jul 23
424B5
Prospectus supplement for primary offering
13 Jul 23
S-8
Registration of securities for employees
9 Mar 23
S-3
Shelf registration
9 Aug 22
S-8
Registration of securities for employees
21 Mar 22
S-8
Registration of securities for employees
26 Jul 21
424B4
Prospectus supplement with pricing info
23 Jul 21
S-1MEF
Registration of additional securities for an S-1
22 Jul 21
FWP
Free writing prospectus
22 Jul 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
11 Aug 22
DEFA14A
Additional proxy soliciting materials
11 Aug 22
DEF 14A
Definitive proxy
11 Aug 22
Other
EFFECT
Notice of effectiveness
17 Aug 22
CORRESP
Correspondence with SEC
12 Aug 22
UPLOAD
Letter from SEC
11 Aug 22
EFFECT
Notice of effectiveness
23 Jul 21
SEC STAFF
SEC staff action: Order
22 Jul 21
CERT
Certification of approval for exchange listing
21 Jul 21
CORRESP
Correspondence with SEC
20 Jul 21
CORRESP
Correspondence with SEC
20 Jul 21
CORRESP
Correspondence with SEC
12 Jul 21
CORRESP
Correspondence with SEC
1 Jul 21
Ownership